CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
DOI 10.1055/s-0038-1668886
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Hinrichsen, H Klinker, A Stoehr, C John, R Heyne, G Klausen, KG Simon, M Cornberg, M Kuhn, U Naumann, M Bilzer, V Günther, V Witte, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2018
Jahrgang / SeitenJg. 56
Kernaussage aus der Literatur
Abstract-Vorschau
Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
Zitieren
Zitierempfehlung
H Hinrichsen, H Klinker, A Stoehr, C John, R Heyne, G Klausen, KG Simon, M Cornberg, M Kuhn, U Naumann, M Bilzer, V Günther, V Witte, S Zeuzem (2018) Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R). Zeitschrift für Gastroenterologie, 56 (08). https://doi.org/10.1055/s-0038-1668886
Mit CareLit weiterarbeiten